The Russian government is considering tightening its pricing policy in the domestic market for essential drugs, with the aim of preventing unreasonable price rises for them in the future.
According to the Russian Ministry of Health, it is planned that ceiling prices for foreign essential drugs sold in Russia will not exceed the average European prices for the same types of drugs. In addition, the producers and sellers of such drugs will not be able to raise prices for such drugs at their own wish.
The implementation of the project is personally controlled by Russia’s first Deputy Prime Minister Igor Shuvalov, who has already instructed the country’s Federal Antimonopoly Service and the Ministry of Health to conduct checks in the Russian regions with the aim to evaluate the rate of availability of vital drugs to local populations and the level of competition in the market.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze